Novo Nordisk A/S (NYSE:NVO) Issues Earnings Results, Meets Estimates

Novo Nordisk A/S (NYSE:NVO - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported $0.92 EPS for the quarter, hitting analysts' consensus estimates of $0.92, Zacks reports. The business had revenue of $11.87 billion for the quarter, compared to analyst estimates of $79.17 billion. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Novo Nordisk A/S updated its FY 2025 guidance to EPS.

Novo Nordisk A/S Stock Performance

NYSE NVO traded up $0.90 on Friday, reaching $65.75. 13,058,660 shares of the stock were exchanged, compared to its average volume of 6,383,307. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15. The company's 50-day simple moving average is $69.21 and its two-hundred day simple moving average is $86.03. The firm has a market capitalization of $295.06 billion, a PE ratio of 19.98, a PEG ratio of 0.90 and a beta of 0.65.

Institutional Trading of Novo Nordisk A/S

An institutional investor recently raised its position in Novo Nordisk A/S stock. Revolve Wealth Partners LLC raised its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 8.7% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 2,490 shares of the company's stock after purchasing an additional 200 shares during the period. Revolve Wealth Partners LLC's holdings in Novo Nordisk A/S were worth $214,000 at the end of the most recent reporting period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. StockNews.com upgraded shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 25th. BNP Paribas started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an "underperform" rating on the stock. Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Finally, Morgan Stanley began coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of "Moderate Buy" and a consensus price target of $135.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.